Positions

Overview

  • Gattadahalli M. Anantharamaiah, Ph.D., professor in the University of Alabama at Birmingham School of Medicine, has been elected as a 2019 National Academy of Inventors fellow.

    Regarded as the highest professional distinction for leading academic inventors, NAI fellows are recognized for their contributions to society.

    Anantharamaiah has dedicated his nearly 50-year career to the advancement of peptide synthesis and protein analysis and is an international expert in the structure and function of plasma apolipoproteins. He holds appointments in the Comprehensive Center for Healthy Aging, O’Neal Comprehensive Cancer Center, UAB Center for AIDS Research, and UAB Nutrition Obesity Research Center. He is associate director of the Atherosclerosis Research Unit, and director of its peptide laboratory.

    Among the university’s most patented inventors, Anantharamaiah holds 19 issued United States patents and 45 issued foreign patents in the field of peptide synthesis. Seventeen of his discoveries have been licensed, generating nearly $2.1 million in license fees and royalties to date. He has published 228 peer-reviewed papers, two books and book chapters and has published or presented more than 70 abstracts on apolipoprotein structure and function and peptide synthesis. He has served as an investigator on more than 30 grant awards throughout his career.

    Development of his novel discovery shows significant potential as therapies for Alzheimer’s disease, heart disease, cancer, asthma, systemic inflammation and other diseases. A partnership with LipimetiX Development, Inc., a clinical stage biotechnology company, has resulted in development of potent Apo E mimetics that Anantharamaiah believes may be the most powerful lipid reduction agents yet discovered. The newer generation analogues insert into cholesterol-rich lipoproteins to direct them to the liver for removal, resulting in dramatically decreased blood cholesterol levels in animal models. The technology is currently being pursued worldwide as a therapy for treating hypercholesterolemia and is on track for first-in-human studies.

    Anantharamaiah joins the seven UAB faculty previously elected to the NAI fellows program. The complete list of NAI Fellows is available on the NAI website.

    The 2019 class of NAI fellows includes 168 academic inventors representing 135 research universities. Since its 2012 program launch, NAI has inducted 1,228 fellows worldwide from more than 250 universities and research institutes. Collectively, NAI fellows hold more than 41,500 issued U.S. patents, have generated more than 11,000 licensed technologies and companies, generated more than $1.6 trillion in revenue, and created more than 36 million jobs.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Expression, purification, and functional reconstitution of 19F-labeled cytochrome b5 in peptide nanodiscs for NMR studies 2020
    2020 Structural Interaction of Apolipoprotein A-I Mimetic Peptide with Amyloid-β Generates Toxic Hetero-oligomers 2020
    2019 Apolipoprotein A-I mimetics mitigate intestinal inflammation in a COX2-dependent inflammatory disease model 2019
    2019 Corrigendum to “Solid-state NMR structural investigations of peptide-based nanodiscs and of transmembrane helices in bicellar arrangements” [Chem. Phys. Lipids 219 (2019) 58–71] (Chemistry and Physics of Lipids (2019) 219 (58–71), (S0009308418302056), (10.1016/j.chemphyslip.2019.01.012)) 2019
    2019 Lipoprotein modulation of proteinuric renal injury 2019
    2019 Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in Human High-density Lipoprotein 2019
    2019 High-resolution structural studies elucidate antiatherogenic and anti-inflammatory properties of peptides designed to mimic amphipathic α-helical domains of apolipoprotein A-I 2019
    2019 Solid-state NMR structural investigations of peptide-based nanodiscs and of transmembrane helices in bicellar arrangements 2019
    2019 The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage 2019
    2019 Probing membrane enhanced protein-protein interactions in a minimal redox complex of cytochrome-P450 and P450-reductase 2019
    2019 Probing protein-protein and protein-substrate interactions in the dynamic membrane-associated ternary complex of cytochromes P450,: B 5, and reductase 2019
    2018 Nanodisc-Forming Scaffold Protein Promoted Retardation of Amyloid-Beta Aggregation 2018
    2018 Supramolecular Organization of Apolipoprotein-A-I-Derived Peptides within Disc-like Arrangements 2018
    2018 Retraction: Crystal structure of human apolipoprotein a-i: Insights into its protective effect against cardiovascular diseases (Proc Natl Acad Sci USA (2006) 103 (2126–2131) DOI: 10.1073/pnas.0506877103) 2018
    2018 A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in Nanodiscs 2018
    2018 Real-Time Monitoring of Lipid Exchange via Fusion of Peptide Based Lipid-Nanodiscs 2018
    2018 Cytochrome-P450-Induced Ordering of Microsomal Membranes Modulates Affinity for Drugs 2018
    2018 ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch’s Membrane and Causes Its Structural Remodeling 2018
    2018 Lipid-exchange in nanodiscs discloses membrane boundaries of cytochrome-P450 reductase 2018
    2018 Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques 2018
    2018 The apolipoprotein e mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophages 2018
    2017 Kinetic and Structural Characterization of the Effects of Membrane on the Complex of Cytochrome b 5 and Cytochrome c 2017
    2017 Cholesterol reduction and macrophage function: Role of paraoxonases 2017
    2017 Membrane environment drives cytochrome P450's spin transition and its interaction with cytochrome: B 5 2017
    2016 Apolipoprotein mimetic peptides as modulators of lipoprotein function 2016
    2016 High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms 2016
    2016 Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux 2016
    2015 Recent developments in modulating atherogenic lipoproteins 2015
    2015 Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer 2015
    2015 Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4F 2015
    2015 Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis 2015
    2015 Novel method for reducing plasma cholesterol: A ligand replacement therapy 2015
    2014 Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A review 2014
    2014 Apolipoprotein A-I mimetics 2014
    2014 Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A 2014
    2014 L-4F Inhibits Lipopolysaccharide-Mediated Activation of Primary Human Neutrophils 2014
    2014 Quantification of HDL particle concentration by calibrated ion mobility analysis 2014
    2014 Searching for a successful HDL-based treatment strategy 2014
    2014 Searching for a successful HDL-based treatment strategy. 2014
    2013 Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid 2013
    2013 Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats 2013
    2013 Recent progress in the development of apoA-I and apoE mimetic therapies 2013
    2013 Anti-Inflammatory Mechanisms of Apolipoprotein A-I Mimetic Peptide in Acute Respiratory Distress Syndrome Secondary to Sepsis 2013
    2013 A novel approach to oral apoA-I mimetic therapy 2013
    2013 Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice 2013
    2013 Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability 2013
    2013 In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathology 2013
    2012 Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F 2012
    2012 Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice 2012
    2012 Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F 2012
    2012 Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides 2012
    2012 D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD 2012
    2012 D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice 2012
    2011 HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats. 2011
    2011 Apolipoprotein E mimetics and cholesterol-lowering properties 2011
    2011 Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma 2011
    2011 Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally 2011
    2011 L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways 2011
    2011 Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function 2011
    2011 Structure and lipid interactions of an anti-inflammatory and anti-atherogenic 10-residue class G* apolipoprotein J peptide using solution NMR 2011
    2010 ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity 2010
    2010 Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice 2010
    2010 Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects 2010
    2010 L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice 2010
    2010 Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer 2010
    2010 The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats 2010
    2010 Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn piglet 2010
    2010 Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages 2010
    2010 Structure and function of HDL mimetics 2010
    2010 Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2 2010
    2010 Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn piglet 2010
    2010 L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation 2010
    2010 Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine 2010
    2009 HDL as a biomarker, potential therapeutic target, and therapy 2009
    2009 A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids 2009
    2009 Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids 2009
    2009 Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats 2009
    2009 Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease 2009
    2009 The role of dysfunctional HDL in atherosclerosis 2009
    2009 Apolipoprotein A-I mimetic peptides. 2009
    2009 Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.). 2009
    2008 Effect of leucine to phenylalanine substitution on the nonpolar face of a class A amphipathic helical peptide on its interaction with lipid: High resolution solution NMR studies of 4F-dimyristoylphosphatidylcholine discoidal complex 2008
    2008 Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I 2008
    2008 HDL therapy for cardiovascular diseases: The road to HDL mimetics 2008
    2008 Multiple indications for anti-inflammatory apolipoprotein mimetic peptides 2008
    2008 Apo A-1 mimetic peptides as atheroprotective agents in murine models 2008
    2008 The Effect of Apolipoprotein Mimetic Peptides in Inflammatory Disorders Other Than Atherosclerosis 2008
    2008 D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet 2008
    2007 Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits 2007
    2007 High-density lipoprotein: Antioxidant and anti-inflammatory properties 2007
    2007 Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides 2007
    2007 Peptide mimetics of apolipoproteins improve HDL function 2007
    2007 Apolipoprotein A-I Mimetic Peptides and Their Role in Atherosclerosis Prevention 2007
    2007 ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers 2007
    2006 Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention 2006
    2006 D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet 2006
    2006 Mechanisms of disease: Proatherogenic HDL - An evolving field 2006
    2006 Atherosclerosis and vascular disease: Effects of peptide mimetics of apolilpoproteins 2006
    2006 Potential clinical utility of high-density lipoprotein-mimetic peptides 2006
    2006 Synthetic peptides: Managing lipid disorders 2006
    2006 Association of a model class A (apolipoprotein) amphipathic α helical peptide with lipid: High resolution NMR studies of peptide-lipid discoidal complexes 2006
    2006 Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases 2006
    2006 Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1 2006
    2006 Oral amphipathic peptides as therapeutic agents 2006
    2005 An apolipoprotein A-I mimetic works best in the presence of apolipoprotein A-I 2005
    2005 Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice 2005
    2005 An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice 2005
    2005 Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide 2005
    2005 ApoA-I mimetic peptides as anti-inflammatory agents 2005
    2005 Apolipoprotein A-I mimetic peptides - ATVB in focus 2005
    2005 D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice 2005
    2005 Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits 2005
    2005 The role of high-density lipoprotein in inflammation 2005
    2004 Two homologous apolipoprotein AI mimetic peptides: Relationship between membrane interactions and biological activity 2004
    2004 Human apolipoprotein A-I and A-I mimetic peptides: Potential for atherosclerosis reversal 2004
    2004 Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids 2004
    2004 D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes 2004
    2004 Double belt structure of discoidal high density lipoproteins: Molecular basis for size heterogeneity 2004
    2004 Antiinflammatory properties of HDL 2004
    2004 Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells 2004
    2004 The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport 2004
    2004 Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux 2004
    2004 Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity 2004
    2004 An Apolipoprotein AI Mimetic Peptide: Membrane Interactions and the Role of Cholesterol 2004
    2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. 2004
    2003 Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis 2003
    2003 A quantitative analysis of apolipoprotein binding to SR-BI: Multiple binding sites for lipid-free and lipid-associated apolipoproteins 2003
    2003 Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice 2003
    2002 Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization 2002
    2002 Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide 2002
    2002 Sustained-delivery of an apolipoproteinE-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels 2002
    2002 Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol 2002
    2001 Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide 2001
    2001 Toward the design of peptide mimics of antiatherogenic apolipoproteins A-I and E 2001
    2001 Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo 2001
    2001 NMR conformational analysis of cis and trans proline isomers in the neutrophil chemoattractant, N-acetyl-proline-glycine-proline 2001
    2001 A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis 2001
    2001 Solution NMR structure of a model class A (apolipoprotein) amphipathic α helical peptide 2001
    2001 Structural models of human apolipoprotein A-I: A critical analysis and review 2001
    2001 Effect of magainin, class L, and class A amphipathic peptides on fatty acid spin labels in lipid bilayers 2001
    2001 Osmotically induced membrane tension modulates membrane permeabilization by class L amphipathic helical peptides: Nucleation model of defect formation 2001
    2000 Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1 2000
    2000 Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3 2000
    2000 Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic α-helix as a recognition motif 2000
    2000 A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples 2000
    2000 Structure and function of apolipoprotein A-I and high-density lipoprotein 2000
    2000 The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts 2000
    1999 Pre-beta-HDL stimulates placental lactogen release from human trophoblast cells. 1999
    1999 Pre-β-HDL stimulates placental lactogen release from human trophoblast cells 1999
    1999 Apolipoprotein-mediated plasma membrane microsolubilization: Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid 1999
    1999 Bioactivity of peptide analogs of the neutrophil chemoattractant, N- acetyl-proline-glycine-proline 1999
    1998 The lipid-free structure of apolipoprotein A-I: Effects of amino- terminal deletions 1998
    1998 Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic α-helixes 1998
    1998 Studies of kinetics and equilibrium membrane binding of class A and class L model amphipathic peptides 1998
    1997 Effect of vesicle size on their interaction with class A amphipathic helical peptides 1997
    1997 Interaction of class A amphipathic helical peptides with phospholipid unilamellar vesicles 1997
    1997 Role of lipids in the permeabilization of membranes by class L amphipathic helical peptides 1997
    1997 Truncation of the amine terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation 1997
    1996 Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-like protein 1996
    1996 Probing structure and function of VLDL by synthetic amphipathic helical peptides 1996
    1996 Chromatographic methods for quantitation of apolipoprotein A-I 1996
    1996 Only the two end helixes of eight tandem amphipathic helical domains of human Apo A-I have significant lipid affinity: Implications for HDL assembly 1996
    1995 Molecular Basis for Prokaryotic Specificity of Magainin-Induced Lysis 1995
    1995 Structural models of human apolipoprotein A-I 1995
    1995 Effect of the arrangement of tandem repeating units of class A amphipathic α-helixes on lipid interaction 1995
    1995 Effect of the cholesterol content of reconstituted LpA-I on lecithin:cholesterol acyltransferase activity 1995
    1995 Efflux of Cellular Cholesterol and Phospholipid to Lipid-Free Apolipoproteins and Class A Amphipathic Peptides 1995
    1995 Localization of a Domain in Apolipoprotein E with both Cytostatic and Cytotoxic Activity 1995
    1995 Mechanisms for the modulation of membrane bilayer properties by amphipathic helical peptides 1995
    1995 Microenvironments of Basic Amino Acids in Amphipathic a-Helices Bound to Phospholipid: 13C NMR Studies Using Selectively Labeled Peptides 1995
    1994 Binding of apolipoprotein A-I model peptides to lipid bilayers. Measurement of binding isotherms and peptide-lipid headgroup interactions 1994
    1994 The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein 1994
    1994 ApoB-100 has a pentapartite structure composed of three amphipathic α-helical domains alternating with two amphipathic β-strand domains: Detection by the computer program LOCATE 1994
    1994 HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity 1994
    1994 Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids. Evidence for the snorkel hypothesis 1994
    1994 Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride- rich lipoproteins 1994
    1994 Mixing rates can markedly affect the kinetics of peptide-induced leakage from liposomes 1994
    1994 Pathogenesis of atherosclerosis 1994
    1994 Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol 1994
    1994 The amphipathic α helix: A multifunctional structural motif in plasma apolipoproteins 1994
    1993 An insulin receptor peptide (1135-1156) stimulates guanosine 5'[γ-thio]triphosphate binding to the 67 kDa G-protein associated with the insulin receptor 1993
    1993 Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins 1993
    1993 Effect of end group blockage on the properties of a class A amphipathic helical peptide 1993
    1993 Reciprocal effects of apolipoprotein and lytic peptide analogs on membranes. Cross-sectional molecular shapes of amphipathic α helixes control membrane stability 1993
    1993 Solution structure of the v3 loop of a thailand hiv isolate 1993
    1992 Computer programs to identify and classify amphipathic α helical domains 1992
    1992 Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein 1992
    1992 The amphipathic helix in the exchangeable apolipoproteins: A review of secondary structure and function 1992
    1992 Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats: Correlation with physical properties 1992
    1991 Apolipoprotein A-I decreases neutrophil degranulation and superoxide production 1991
    1991 Role of amphipathic helixes in HDL structure/function 1991
    1991 Erratum: Amphipathic helix motif: Classes and properties (Proteins (1990) 8 (103-117)) 1991
    1991 Inhibition of virus‐induced cell fusion by apolipoprotein A‐I and its amphipathic peptide analogs 1991
    1990 Thermodynamics of the binding of human apolipoprotein A-I to dimyristoylphosphatidylglycerol 1990
    1990 Nuclear magnetic resonance investigation of the interaction with phospholipid of an amphipathic α-helix-forming peptide of the apolipoprotein class 1990
    1990 Interactions of Serum Proteins with Small Unilamellar Liposomes Composed of Dioleoylphosphatidylethanolamine and Oleic Acid: High-Density Lipoprotein, Apolipoprotein A1, and Amphipathic Peptides Stabilize Liposomes 1990
    1990 Amphipathic helix motif: Classes and properties 1990
    1990 Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs 1990
    1990 Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation 1990
    1990 Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-I 1990
    1989 Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: Use of this peptide sequence in the synthesis of biologically active peptides 1989
    1989 Properties of lipid complexes with amphipathic helix-forming peptides. Role of distribution of peptide charges 1989
    1989 Synthetic amphipathic peptides resembling apolipoproteins stimulate the release of human placental lactogen 1989
    1988 Effect of oxidation on the properties of apolipoproteins A-1 and A-II 1988
    1987 Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I. 1987
    1987 Synthesis of 3-O-β-d-xylopyranosyl-l-serine (xylosylserine) and O-β-d-galactopyranosyl-(1-4)-O-β-d-xylopyranosyl-l-serine (galactosylxylosylserine) and use of the synthetic products for detection of galactosyltransferase I activity in rat liver 1987
    1987 Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation. 1987
    1987 Structural and biological studies on synthetic peptide analogues of a low-affinity calcium-binding site of skeletal troponin C 1987
    1987 Characterization of high density lipoprotein subspecies: Structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatography 1987
    1986 [36] Synthetic Peptide Analogs of Apolipoproteins 1986
    1985 Studies of synthetic peptide analogs of the amphiphatic helix. Structure of complexes with dimyristoyl phosphatidylcholine 1985
    1982 Resolution of α-methyl amino esters by chymotrypsin 1982
    1980 Use of immobilized carboxypeptidase Y (I-CPY) as a catalyst for deblocking in peptide synthesis 1980
    1979 Removal of Benzyl-Type Protecting Groups from Peptides by Catalytic Transfer Hydrogenation with Formic Acid 1979
    1977 Transfer hydrogenation; a convenient method for removal of some commonly used protecting groups in peptide synthesis 1977
    1974 FIBRINOPEPTIDES. III. SYNTHESIS OF THE PROTECTED NONAPEPTIDE SEQUENCE OF FIBRINOPEPTIDE‐B OF GREEN MONKEY 1974

    Book

    Year Title Altmetric
    2002 Experimental and computational studies of the interactions of amphipathic peptides with lipid surfaces.  Ed. 52.  2002

    Chapter

    Year Title Altmetric
    2010 HDL mimetic peptides: Novel therapeutic strategies for the treatment of inflammatory vascular disease.  179-197. 2010
    2008 HDL and Inflammation.  339-354. 2008

    Education And Training

  • Doctor of Philosophy in Biochemistry, Bangalore University 1978

    • Full Name

  • Gattadahalli Anantharamaiah